With the approval of more than a dozen immunotherapies and targeted therapies for the treatment of cancer, patients have more options than ever before to treat their disease.
However, the risk of adverse events is always present. With immunotherapy, and when you include combination therapy with a targeted medication, 30-60 percent of patients will have a hair, skin, or nail reaction, according to Anisha Patel, MD, FAAD, an associate professor of dermatology and internal medicine at The University of Texas MD Anderson Cancer Center in Houston.